TC
ADMS

TFS Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

TFS Capital’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-62,318
Closed -$943K – 1072
2016
Q2 		$943K Buy
+62,318
New +$1.03M 0.17% 188
2016
Q1 		– Sell
-60,709
Closed -$1.72M – 1135
2015
Q4 		$1.72M Sell
60,709
-98,582
-62% -$1.66M 0.19% 197
2015
Q3 		$2.67M Buy
159,291
+61,639
+63% +$1.4M 0.26% 101
2015
Q2 		$2.56M Sell
97,652
-791
-0.8% -$15.4K 0.25% 99
2015
Q1 		$1.72M Buy
98,443
+10,257
+12% +$176K 0.17% 179
2014
Q4 		$1.53M Buy
+88,186
New +$1.34M 0.15% 197

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
BS
Bow Street New York $52.4M AUM 2.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

TFS Capital's ADMS Position: Q3 2016 in Review

TFS Capital sold out of Adamas Pharmaceuticals (ADMS) in Q3 2016, closing a stake of 62,318 shares — an estimated $943K sold.

TFS Capital first reported a position in ADMS in Q4 2014 and held it in 6 quarters. The position peaked at $2.67M in Q3 2015. 81 funds tracked by Wall St. Rank hold ADMS as of Q3 2016.

  • TFS Capital reported no remaining Adamas Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • TFS Capital sold 62,318 Adamas Pharmaceuticals shares in Q3 2016, an estimated $943K.
  • TFS Capital first reported a position in Adamas Pharmaceuticals in Q4 2014 and held it in 6 quarters.
  • TFS Capital's Adamas Pharmaceuticals position peaked at $2.67M in Q3 2015.
  • 81 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.